NDC 0002-7190

LARTRUVO

Olaratumab

LARTRUVO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Olaratumab.

• Product ID: 0002-7190_3186948d-039a-4bff-8cca-42bd09c773b9
• NDC: 0002-7190
• Product Type: Human Prescription Drug
• Proprietary Name: LARTRUVO
• Generic Name: Olaratumab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2016-10-19
• Marketing Category: BLA / BLA
• Application Number: BLA761038
• Labeler Name: Eli Lilly and Company
• Substance Name: OLARATUMAB
• Active Ingredient Strength: 10 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2019-12-31

Packaging

NDC 0002-7190-01

1 VIAL, SINGLE-USE in 1 CARTON (0002-7190-01) > 19 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2017-02-14
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0002-7190-01 [00002719001]

LARTRUVO INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761038
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2017-02-14
• Marketing End Date: 2020-11-27

Drug Details

Active Ingredients

Ingredient	Strength
OLARATUMAB	10 mg/mL

OpenFDA Data

• SPL SET ID: 6a5bff43-f922-46ae-a727-d54d9138c46e
• Manufacturer:
  • Eli Lilly and Company
• UNII:
  • TT6HN20MVF
• RxNorm Concept Unique ID - RxCUI:
  • 1855744
  • 1855739
  • 1872478
  • 1872479

NDC Crossover Matching brand name "LARTRUVO" or generic name "Olaratumab"

NDC	Brand Name	Generic Name
0002-7190	LARTRUVO	olaratumab
0002-8926	LARTRUVO	olaratumab